A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 4 Active not recruiting 63 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) \[New York Heart Association (NYHA) Functional Class II or III\].

Timeline

Start: 2024-01-24
Primary completion: 2026-07-09
Completion: 2026-07-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mavacamten	Small molecule	—	—

Indications

No indication recorded.